Pharmacy

Your Article Summary

See Latest Articles

New study results further support the efficacy and safety of a once daily Mirapexin/Sifrol (pramipexole) formulation at all stages of Parkinson`s disease, with added benefits in the reduction of off-time
Boehringer Ingelheim, 06/11/09

New data presented at the Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders further confirms high therapeutic benefit of Mirapexin/Sifrol once-daily, extended release formulation. The trial, performed in patients with advanced Parkinson's disease, showed results comparable to pramipexole's already long-established immediate release formulation.

Today in Major Studies...keeping you current

Receive free subspecialty "5-minute updates" via email

Evaluation of Treatment Satisfaction in Children with Allergic Disease Treated with an Antihistamine: An International, Non-Interventional, Retrospective Study
Clinical Drug Investigation, 12/11/09

Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded in Latin America
Sanofi-aventis, 12/10/09

Allos Therapeutics' FOLOTYN Shows Activity in a Dose Finding Phase 1 Study of Relapsed or Refractory Cutaneous T-Cell Lymphoma
Allos Therapeutics, 12/09/09

 See all of Major Studies

Today in Neuro/Psych pharmacology...keeping you current

Receive free subspecialty "5-minute updates" via email

Behavioral Dimensions and Acetylcholinesterase Inhibitor-related Effect in Alzheimer Disease Over Time: A Latent Trajectory Modeling
Cognitive and Behavioral Neurology, 12/10/09

Natalizumab treatment in multiple sclerosis: Marked decline of chemokines and cytokines in cerebrospinal fluid
Multiple Sclerosis, 12/10/09

Depression in Parkinson's Disease
Canadian Journal of Neurological Sciences, 12/10/09

 See all of Neuro/Psych pharmacology